Graduate Student Research Achievements Site
日本語>>
TOP page
SAKAI Ryuutaro
Department / Course
Ritsumeikan University Graduate School Graduate School of Life Sciences Major in Advanced Life Sciences
Job
Academic conference attendance and presentation
2026/09/08
Health Economic Evaluation of Pancreatic Cancer Risk Control Using Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) in BRCA1/2 Pathogenic Variant Carriers (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)
2026/09/07
Cost-Effectiveness Analysis of Atezolizumab plus Bevacizumab Combination Therapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)
2026/09/07
Health Economic Evaluation Model for Breast Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) in BRCA1/2 Pathogenic Variant Carriers (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)
2025/11/09
Health Economic Evaluation Model for Breast Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)
2025/11/09
Health Economic Evaluation Model for Ovarian Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)
2025/11/09
Health Economic Evaluation Model for Pancreatic Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)
2025/11/09
Health Economic Evaluation Model for Prostate Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)
2024/05/08
Cost-Effectiveness Analysis of Tremelimumab As First-Line Therapy for Metastatic Non-Small Cell Lung Cancer in Japan (International Society for Pharmacoeconomics and Outcomes Research（ISPOR）)
